BioPlus Acquisition Corp. Warrants
BIOSW
BIOSW was delisted on the 6th of October, 2023.
42 hedge funds and large institutions have $3.79M invested in BioPlus Acquisition Corp. Warrants in 2022 Q1 according to their latest regulatory filings, with 42 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Saba Capital Management
New York
|
+$196K |
| 2 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$149K |
| 3 |
LA
Linden Advisors
New York
|
+$130K |
| 4 |
Goldman Sachs
New York
|
+$107K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$97.4K |
Top Sellers
BIOSW Hedge Fund Activity: Q1 2022 in Review
42 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in BioPlus Acquisition Corp. Warrants (BIOSW) for Q1 2022, worth a combined $3.79M.
Buyers outnumbered sellers: 42 funds opened new BIOSW positions and 0 closed out — a net gain of 42 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Saba Capital Management, opening a new position worth an estimated $196K.
- 42 institutional investors held BioPlus Acquisition Corp. Warrants (BIOSW) as of Q1 2022, up from 0 in Q4 2021.
- Funds reported $3.79M of BioPlus Acquisition Corp. Warrants stock for Q1 2022.
- 42 funds opened new BioPlus Acquisition Corp. Warrants positions in Q1 2022 and 0 closed out, a net change of +42 holders.
- The largest BioPlus Acquisition Corp. Warrants buyer in Q1 2022 was Saba Capital Management, an estimated $196K added.
Based on aggregated 13F filings for Q1 2022.